Biogen Idec 2011 total revenues boost 7 percent to $5.

Non-GAAP diluted EPS for 2011 were $5.90, a rise of 15 percent over 2010. Non-GAAP net gain due to Biogen Idec for 2011 was $1.4 billion, a rise of around 10 percent versus 2010. 4th Quarter 2011 Highlights: 4th quarter revenues increased 9 percent to $1.3 billion, when compared to fourth quarter of 2010. TYSABRI revenues increased 11 percent year-over-calendar year to $269 million while AVONEX revenues increased 8 percent year-over-12 months to $703 million. RITUXAN revenues from our unconsolidated joint business set up had been $258 million for the quarter, approximately in-line with the last year. Global in-market product sales of TYSABRI in the 4th one fourth of 2011 were $380 million, a rise of 14 percent over the fourth quarter of 2010.But when it involves cancer, say UCLA experts, mother cells may be far more prolific. Bioengineers at the UCLA Henry Samueli College of Engineering and Applied Technology developed a system to mechanically confine cells, simulating the in three-dimensional environments where they divide vivo, and discovered that, upon confinement, cancer cells often put into three or even more daughter cells. We hope that platform allows us to raised know how the 3-D mechanical environment may are likely involved in the progression of a benign tumor right into a malignant tumor that kills, stated Dino Di Carlo, a co-employee professor of bioengineering at UCLA and principal investigator on the study.

Other Posts From "obstetrics":

Related Posts